PROGRAMMABLE POLYMERIC DRUGS

1 . A compound having the following structure (I):

or a stereoisomer, pharmaceutically acceptable salt or tautomer thereof, wherein:

M is, at each occurrence, independently a biologically active moiety, or fragment thereof, a prodrug of a biologically active moiety, or fragment thereof, a fluorescent dye, an imaging agent, or a radioisotope binding site, provided at least one occurrence of M is not a fluorescent dye;

L is an optional linker provided that at least one occurrence of L comprises more than 4 carbons or at least one occurrence of L comprises oxygen;

L 1 and L 2 are, at each occurrence, independently an optional alkylene linker;

R 1 is, at each occurrence, independently H, alkyl or alkoxy;

R 2 and R 3 are each independently absent, H, OH, SH, alkyl, alkoxy, alkylether, heteroalkyl, dT, —OP(═R a )(R b )R c , Q, or a protected form thereof, or L′;

R 4 is, at each occurrence, independently O − , S − , OZ, SZ or N(R 6 ) 2 , where Z is a cation and each R 6 is independently H or alkyl;

R 5 is, at each occurrence, independently oxo, thioxo or absent;

R a is O or S;

R b is OH, SH, O − , S − , OR d or SR d ;

R c is OH, SH, O − , S − , OR d , OL′, SR d , OdT, alkyl, alkoxy, heteroalkyl, heteroalkoxy, alkylether, alkoxyalkylether, phosphate, thiophosphate, phosphoalkyl, thiophosphoalkyl, phosphoalkylether or thiophosphoalkylether;

R d is a counter ion;

Q is, at each occurrence, independently a moiety comprising a reactive group, or protected form thereof, capable of forming a covalent bond with a complementary reactive group Q on a targeting moiety;

L′ is, at each occurrence, independently a linker comprising a covalent bond to Q, a targeting moiety, a linker comprising a covalent bond to a targeting moiety, a linker comprising a covalent bond to a solid support, a linker comprising a covalent bond to a solid support residue, a linker comprising a covalent bond to a nucleoside or a linker comprising a covalent bond to a further compound of structure (I); and

n is an integer of one or greater.

2 . (canceled)

3 . (canceled)

4 . The compound of claim 1 , having the following structure (IA):

wherein:

a and b are, at each occurrence, independently an integer from 0 to 10.

5 .- 8 . (canceled)

9 . The compound of claim 1 , wherein at least one occurrence of L comprises an amide bond, an ester bond, a phosphodiester bond, a disulfide bond, a double bond, a triple bond, an ether bond, a hydrazone, an amino acid sequence, a ketone, a diol, a cyano, a nitro or combinations thereof.

10 . The compound of claim 9 , wherein at least one occurrence of L comprises an amino acid sequence recognized by a sortase enzyme.

11 . The compound of claim 10 , wherein the amino acid sequence is Leu-Pro-X-Thr-Gly, wherein X is any amino acid residue.

12 . (canceled)

13 . (canceled)

14 . The compound of claim 1 , wherein at least one occurrence of L comprises one of the following structures:

15 .- 21 . (canceled)

22 . The compound of claim 1 , wherein at least one occurrence of L comprises one of the following structures:

23 .- 27 . (canceled)

28 . The compound of claim 1 , wherein at least one occurrence of L comprises a linker that is non-cleavable under physiological conditions.

29 . The compound of claim 1 , wherein at least one occurrence of L comprises a thioether bond.

30 . (canceled)

31 . The compound of claim 28 , wherein at least one occurrence of L comprises one of the following structures:

32 .- 44 . (canceled)

45 . The compound of claim 144 , wherein L′ has the following structure:

wherein

m″ and n″ are independently an integer from 1 to 10;

R c is H, an electron pair or a counter ion;

L″ is the targeting moiety or a linkage to the targeting moiety.

46 . (canceled)

47 . The compound of claim 1 , wherein the targeting moiety is an antibody or cell surface receptor antagonist.

48 . (canceled)

49 . (canceled)

50 . The compound of claim 47 , wherein the targeting moiety is a monoclonal antibody, wherein the monoclonal antibody is Abciximab, Adalimumab, Alemtuzumab, Alirocumab, Avibactam, Basiliximab, Benralizumab, Bezlotoxumab, Blinatumomab, Brodalumab, Burosumab, Canakinumab, Caplacizumab, Certolizumab pegol, Daclizumab, Denosumab, Dupilumab, Eculizumab, Emicizumab, Erenumab, Evolocumab, Fremanezumab, Galcanezumab, Golimumab, Guselkumab, Ibalizumab, Idarucizumab, Infliximab, Itolizumab, Ixekizumab, Lanadelumab, Lokivetmab, Mepolizumab, Natalizumab, Obiltoxaximab, Ocrelizumab, Omalizumab, Palivizumab, Ranibizumab, Raxibacumab, Reslizumab, Rmab, Rovelizumab, Ruplizumab, Sarilumab, Secukinumab, Tildrakizumab, Thiomab, Tocilizumab, Ustekinumab, Vedolizumab, Abrilumab, Actoxumab, Aducanumab, Afasevikumab, Afelimomab, Anifrolumab, Anrukinzumab (IMA-638), Aselizumab, Atorolimumab, Bapineuzumab, BCD-100, Bertilimumab, Besilesomab, Biciromab, Bimagrumab, Bimekizumab, Birtamimab, Bleselumab, Blosozumab, Bococizumab, Brazikumab, Briakinumab, Brolucizumab, Carlumab, Carotuximab, Cedelizumab, Clazakizumab, Clenoliximab, Concizumab, Cosfroviximab, CR6261, Crenezumab, Crizanlizumab, Crotedumab, Depatuxizumab, mafodotin, Derlotuximab biotin, Dezamizumab, Diridavumab, Domagrozumab, Dusigitumab, Ecromeximab, Edobacomab, Efalizumab, Efungumab, Eldelumab, Elezanumab, Enokizumab, Eptinezumab, Erlizumab, Etrolizumab, Evinacumab, Exbivirumab, Fanolesomab, Faralimomab, Faricimab, Fasinumab, Felvizumab, Fezakinumab, Flanvotumab, Fletikumab, Flotetuzumab, Fontolizumab, Foravirumab, Frovocimab, Fulranumab, Gantenerumab, Gavilimomab, Gevokizumab, Gimsilumab, Gomiliximab, Gosuranemab, Ianalumab, Inclacumab, Inolimomab, Iomab-B, Keliximab, Lampalizumab, Landogrozumab, Larcaviximab, Lebrikizumab, Lenvervimab, Lerdelimumab, Letolizumab, Libivirumab, Ligelizumab, Lodelcizumab, Lulizumab pegol, Marstacimab, Mavrilimumab, Metelimumab, Mirikizumab, Motavizumab, Muromonab CD3, Nebacumab, Nemolizumab, NEOD001, Nirsevimab, Odulimomab, Olendalizumab, Olokizumab, OMS721, Opicinumab, Orticumab, Otelixizumab, Otilimab, Oxelumab, Ozanezumab, Ozoralizumab, Pagibaximab, Panobacumab, Pascolizumab, Pateclizumab, PDR001, Perakizumab, Pexelizumab, Placulumab, Plozalizumab, Ponezumab, Porgaviximab, Prasinezumab, Priliximab, PRO 140, Quilizumab, Rafivirumab, Ralpancizumab, Ranevetmab, Ravagalimab, Ravulizumab, Refanezumab, Regavirumab, Relatlimab, Rinucumab, Risankizumab, Roledumab, Romosozumab, Rontalizumab, SA237, Satralizumab, Sevirumab, SHP647, Sifalimumab, Simtuzumab, Siplizumab, Sirukumab, Solanezumab, Sonepcizumab, Spartalizumab, Stamulumab, Sulesomab, Suptavumab, Sutimlimab, Suvizumab, Suvratoxumab, Tadocizumab, Talizumab, Tamtuvetmab, Tanezumab, Tefibazumab, Telimomab aritox, Teneliximab, Teplizumab, Teprotumumab, Tezepelumab, Tibulizumab, Toralizumab, Tralokinumab, Trevogrumab, Tuvirumab, Ulocuplumab, Urtoxazumab, Varisacumab, Vepalimomab, Vesencumab, Visilizumab, Vobarilizumab, Zolimomab aritox, trastuzumab, gemtuzumab, brentuximab, vorsetuzumab, lorvotuzumab, cantuzumab, bivatuzumabor inotuzumab, or vadastuximab.

51 . The compound of claim 1 , wherein R 2 or R 3 has one of the following structures:

52 . The compound of claim 1 , wherein R 3 has the following structure:

53 .- 56 . (canceled)

57 . The compound of claim 1 , wherein

A) at least one occurrence of M is an antineoplastic agent, an enediyne antitumor antibiotic, a maytansinoid, a topoisomerase inhibitor, a kinase inhibitor, an anthracycline, and EGFR inhibitor or an alkylating agent;

B) at least one occurrence of M is an antineoplastic agent, an enediyne antitumor antibiotic, a maytansinoid, a topoisomerase inhibitor, or an alkylating agent;

C) at least one occurrence of M is selected from the group consisting of auristatin F, monomethyl auristatin F, monomethyl auristatin E, paciltaxol, SN-38, calicheamicin, anthramycin, abbeymycin, chicamycin, DC-81, mazethramycin, neothramycin A neothramycin B, porothramycin prothracarcin, sibanomicin, sibiromycin, tomamycin, mertansine, emtansine, irinotecan, camptothecin, topotecan, silatecan, cositecan, Exatecan, Lurtotecan, gimatecan, Belotecan, and Rubitecan; or

D) at least one occurrence of M has one of the following structures:

58 .- 63 . (canceled)

64 . The compound of claim 1 , wherein the compound has one of the following structures:

wherein,

F has the following structure:

dT has the following structure:

wherein:

R is H or a direct bond.

65 . A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

66 . A method of treating a disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 65 , wherein at least one M is a biologically active moiety effective for treating the disease.

67 .- 83 . (canceled)

84 . A compound having one of the following structures:

wherein:

Fmoc has the following structure:

and

DMTr has the following structure: